首页> 外文期刊>Journal of Thoracic Disease >Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue?
【24h】

Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue?

机译:急性心肌梗死后常规的β-受体阻滞剂给药:为什么仍未解决?

获取原文
           

摘要

Since the 1980s, the mortality from myocardial infarction (MI) has regressed by approximately 25% in Western countries, not only due to the development of routine defibrillation, monitored units and early coronary reperfusion but also to the introduction of antiplatelet therapies, angiotensin-converting enzyme (ACE) inhibitors/ angiotensin-receptor blockers (ARBs), statins and betablockers.
机译:自1980年代以来,西方国家因心肌梗死(MI)导致的死亡率下降了约25%,这不仅是由于常规除颤,监测单位和早期冠状动脉再灌注的发展,而且还因为采用了抗血小板疗法,血管紧张素转换酶(ACE)抑制剂/血管紧张素受体阻滞剂(ARB),他汀类药物和β受体阻滞剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号